Osteometer wins US market clearance for bone marker test
This article was originally published in Clinica
The US FDA has cleared Osteometer Biotech's serum-based bone resorption test for monitoring antiresorptive therapy in patients with osteoporosis. The Serum CrossLaps One Step ELISA test, which detects collagen fragments released into circulation during bone resorption, can also be used as an early test for predicting the long-term skeletal response to antiresorptive treatments, such as Fosamax and hormone replacement therapy (HRT).
You may also be interested in...
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.